Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson's disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer's disease. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida. Show more

Location: 100 SE 2nd Street, Miami, FL, 33131, United States | Website: https://telomirpharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

34.82M

52 Wk Range

$1.12 - $8.40

Previous Close

$1.17

Open

$1.18

Volume

398,100

Day Range

$1.13 - $1.20

Enterprise Value

36.89M

Cash

403K

Avg Qtr Burn

-998.5K

Insider Ownership

34.17%

Institutional Own.

12.53%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date